Sources

9 Total Sources

FDA Panel Backs Replimune's RP1 in 10-3 Vote as Shares Jump 127%

Left20%
Center40%
Right40%
Yahoo Finance5d ago
FDA Panel Backs Replimune's RP1 for Advanced Melanoma, Shares Soar
The Wall Street Journal5d ago
FDA Panel Votes In Favor of Replimune's Melanoma Treatment - WSJ
app.dealroom.co5d ago
FDA staff question Replimune's RP1 efficacy ahead of ODAC melanoma vote | Dealroom.co
STAT5d ago
FDA panel endorses Replimune's previously rejected melanoma drug
Medical Daily6d ago
FDA Reviewers Say Melanoma Trial Data Cannot Be Verified as Advisers Weigh a Third Review
Seeking Alpha5d ago
Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review (REPL) | Seeking Alpha
wabx.net5d ago
US FDA advisers back Replimune skin cancer drug trial data | WABX 107.5 | Evansville's Classic Rock Station
Reuters5d ago
US FDA advisers back Replimune skin cancer drug trial data | Reuters
StockTitan5d ago
Replimune details FDA panel on RP1 melanoma BLA | REPL 8-K Filing